[Part I—FINANCIAL INFORMATION](index=5&type=section&id=Part%20I%E2%80%94FINANCIAL%20INFORMATION) [Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) The company's Q1 2024 financial statements present total assets of $3.06 billion, net revenues of $248.2 million, and net income of $6.3 million [Consolidated Balance Sheets](index=5&type=section&id=Consolidated%20Balance%20Sheets) As of March 31, 2024, total assets were $3.06 billion, total liabilities $2.63 billion, and total equity $429.4 million, reflecting slight decreases from year-end 2023 Consolidated Balance Sheets (in thousands) | Balance Sheet Items | March 31, 2024 (Unaudited) | December 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $261,133 | $296,407 | | Total current assets | $487,179 | $557,244 | | Total assets | $3,059,692 | $3,130,420 | | **Liabilities & Equity** | | | | Total current liabilities | $152,340 | $230,654 | | Long-term debt, less current portion | $2,224,611 | $2,223,674 | | Total liabilities | $2,630,300 | $2,686,686 | | Total equity | $429,392 | $443,734 | [Consolidated Statements of Operations and Comprehensive Income (Loss)](index=7&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income%20%28Loss%29) For Q1 2024, net revenues increased to $248.2 million, operating income nearly doubled to $53.2 million, and net income more than doubled to $6.3 million year-over-year Consolidated Statements of Operations and Comprehensive Income (Loss) (in thousands) | Income Statement Items (in thousands) | Q1 2024 (Unaudited) | Q1 2023 (Unaudited) | | :--- | :--- | :--- | | Total net revenues | $248,176 | $220,590 | | Gross profit | $127,115 | $111,503 | | Operating income | $53,174 | $33,366 | | Interest expense, net | $41,771 | $28,870 | | Net income | $6,323 | $2,842 | | Diluted EPS | $0.02 | $0.01 | [Consolidated Statements of Cash Flows](index=8&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Net cash provided by operating activities significantly decreased to $9.7 million in Q1 2024, primarily due to a $35.0 million litigation settlement payment Consolidated Statements of Cash Flows (in thousands) | Cash Flow Activities (in thousands) | Q1 2024 (Unaudited) | Q1 2023 (Unaudited) | | :--- | :--- | :--- | | Net cash provided by operating activities | $9,699 | $33,871 | | Net cash used in investing activities | ($34,853) | ($44,968) | | Net cash (used in) provided by financing activities | ($11,941) | $273,916 | | Net (decrease) increase in cash | ($38,834) | $263,886 | - A **$35.0 million** payment for the Georgia EO litigation settlement was a significant use of cash from operating activities in Q1 2024[22](index=22&type=chunk) [Notes to Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) The notes provide detailed accounting policies, segment revenue disaggregation, debt structure, and updates on ongoing Ethylene Oxide (EO) litigation - The company operates and reports in three segments: Sterigenics (outsourced sterilization), Nordion (Co-60 supplier), and Nelson Labs (lab testing and advisory services)[28](index=28&type=chunk)[139](index=139&type=chunk) Revenue by Segment (in thousands) | Revenue by Segment (in thousands) | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Sterigenics | $166,497 | $159,997 | | Nordion | $24,007 | $8,551 | | Nelson Labs | $57,672 | $52,042 | | **Total** | **$248,176** | **$220,590** | - Accrued liabilities decreased significantly from **$122.5 million** at year-end 2023 to **$61.8 million** at March 31, 2024, primarily due to the payment of the **$35.0 million** Georgia EO litigation settlement reserve[47](index=47&type=chunk) - The company is involved in multiple Ethylene Oxide (EO) tort lawsuits in Illinois, Georgia, California, and New Mexico, alleging injuries from EO emissions, and is vigorously defending these cases[91](index=91&type=chunk)[94](index=94&type=chunk)[95](index=95&type=chunk) [Management's Discussion and Analysis (MD&A)](index=39&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2024 financial results, highlighting a 12.5% increase in net revenues to $248.2 million and a 13.7% increase in Adjusted EBITDA to $111.9 million Key Financial Metrics (in thousands) | Metric (in thousands) | Q1 2024 | Q1 2023 | % Change | | :--- | :--- | :--- | :--- | | Total net revenues | $248,176 | $220,590 | 12.5% | | Operating income | $53,174 | $33,366 | 59.4% | | Net income | $6,323 | $2,842 | 122.5% | | Adjusted EBITDA | $111,944 | $98,468 | 13.7% | - Revenue growth was driven by a **5.6% increase in service revenues** and a significant **256.8% increase in product revenues**, primarily due to favorable Co-60 harvest schedule timing at Nordion[163](index=163&type=chunk)[164](index=164&type=chunk)[165](index=165&type=chunk) - SG&A expenses decreased by **6.0%** to **$58.2 million**, primarily due to a **$7.6 million** decline in litigation and professional services expenses related to EO sterilization facilities[170](index=170&type=chunk) - The company paid a **$35.0 million** Atlanta EO litigation settlement in January 2024, which was a primary driver for the decrease in cash from operations[160](index=160&type=chunk)[200](index=200&type=chunk)[206](index=206&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=51&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) No material changes to the company's market risks occurred during the three months ended March 31, 2024, compared to the 2023 Form 10-K - Market risks have not materially changed for the three months ended March 31, 2024[221](index=221&type=chunk) [Controls and Procedures](index=51&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2024, with no material changes in internal control over financial reporting during the quarter - The CEO and CFO concluded that the company's disclosure controls and procedures are effective as of the end of the reporting period[222](index=222&type=chunk) - No changes in internal control over financial reporting occurred during Q1 2024 that materially affected, or are reasonably likely to materially affect, internal controls[223](index=223&type=chunk) [Part II—OTHER INFORMATION](index=52&type=section&id=Part%20II%E2%80%94OTHER%20INFORMATION) [Legal Proceedings](index=52&type=section&id=Item%201.%20Legal%20Proceedings.) The company provides updates on material legal proceedings, including EO tort litigation and ongoing settlement negotiations for Notices of Violation at various facilities - The company references Note 14 for details on material legal proceedings, including EO tort litigation in Illinois, Georgia, California, and New Mexico, as well as securities litigation[227](index=227&type=chunk) - A Notice of Violation was received for the Queensbury, NY facility following a power outage and scrubber system failure in May 2023, with ongoing settlement negotiations with the NYS DEC[229](index=229&type=chunk)[230](index=230&type=chunk) - Notices of Violation were issued to the Vernon and Ontario, CA facilities by the SCAQMD related to operational requirements and alleged public nuisance, with the company disputing allegations and in settlement negotiations[231](index=231&type=chunk) [Risk Factors](index=53&type=section&id=Item%201A.%20Risk%20Factors.) Updated risk factors include the final US EPA NESHAP rules for EO sterilization facilities, requiring new pollution control technologies and CEMS by April 6, 2026 - On March 14, 2024, the US EPA announced final NESHAP rules for EO sterilization facilities, requiring additional air pollution technologies and continuous emissions monitoring systems (CEMS)[233](index=233&type=chunk) - The compliance deadline for the new NESHAP rule is April 6, 2026, which the company notes will be challenging and may require capital expenditures beyond current anticipation[234](index=234&type=chunk) [Other Information](index=53&type=section&id=Item%205.%20Other%20Information.) No directors or executive officers adopted or terminated Rule 10b5-1 trading plans or non-Rule 10b5-1 trading arrangements during Q1 2024 - No directors or executive officers adopted or terminated Rule 10b5-1 trading plans during Q1 2024[235](index=235&type=chunk) [Exhibits](index=54&type=section&id=Item%206.%20Exhibits.) This section lists all exhibits filed with the Quarterly Report on Form 10-Q, including officer certifications, credit agreement amendments, and XBRL data files - The Exhibit Index lists all documents filed or furnished as part of the 10-Q report[237](index=237&type=chunk) [Signatures](index=55&type=section&id=SIGNATURES) - The report was signed on May 2, 2024, by Jonathan M. Lyons, Senior Vice President and Chief Financial Officer[241](index=241&type=chunk)

Exhibit 99.1 Sterigenics For first-quarter 2024, net revenues were $166 million, an increase of 4.1% compared to the first quarter a year ago. Segment income was $86 million, an increase of 3.6%. Net revenue growth for first-quarter 2024 was driven by favorable pricing and changes in foreign currency exchange rates, partially offset by unfavorable volume and mix. Sotera Health Reports First-Quarter 2024 Results CLEVELAND, OH, May 2, 2024 – Sotera Health Company ("Sotera Health" or the "Company") (Nasdaq: SH ...

Sotera Health Company (NASDAQ:SHC) Q4 2023 Earnings Conference Call February 27, 2024 9:00 AM ET Company Participants Jason Peterson - Vice President and Treasurer Michael Petras - Chairman and CEO Jon Lyons - Chief Financial Officer Conference Call Participants Sean Dodge - RBC Capital Dave Windley - Jefferies Luke Sergott - Barclays Brett Fishbin - KeyBanc Casey Woodring - JPMorgan Patrick Donnelly - Citi Michael Polark - Wolfe Research Operator Good morning and welcome to the Sotera Health Fourth Quarter ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39729 SOTERA HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 47-3531161 (State or other jurisdiction of incorporation ...

Sotera Health Company (NASDAQ:SHC) Q3 2023 Earnings Conference Call November 1, 2023 9:00 AM ET Corporate Participants Jason Peterson - Vice President and Treasurer Michael Petras - Chairman and Chief Executive Officer Jonathan Lyons - Senior Vice President and Chief Financial Officer Conference Call Participants Sean Dodge - RBC Capital Markets Patrick Donnelly - Citi Michael Polark - Wolfe Research Casey Woodring - JPMorgan Operator Good morning and welcome to the Sotera Health Third Quarter 2023 Conferen ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company ...

Sotera Health Company (NASDAQ:SHC) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Corporate Participants Jason Peterson - Vice President and Treasurer Michael Petras - Chairman and Chief Executive Officer Jonathan Lyons - Chief Financial Officer Conference Call Participants Sean Dodge - RBC Capital David Windley - Jefferies Luke Sergott - Barclays Casey Woodring - JPMorgan Matthew Mishan - KeyBanc Michael Polark - Wolfe Research Operator Good morning, and welcome to the Sotera Health Second Quar ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39729 SOTERA HEALTH COMPANY (Exact name of registrant as specified in its charter) | Delaware | | 47-3531161 | ...

Financial Data and Key Metrics Changes - Total company revenues declined by 6.8% year-over-year to $221 million, with a 5.3% decline on a constant currency basis [88][84] - Adjusted EBITDA decreased by 14.6% compared to the first quarter of 2022, amounting to $98 million, with adjusted EBITDA margins at 44.6%, a decline of 410 basis points [20][24] - Adjusted EPS for the quarter was $0.13, a decrease of $0.09 from the same period last year [20][108] Business Line Data and Key Metrics Changes - Sterigenics reported a 7% revenue growth to $160 million and over 4% segment income growth to $83 million compared to the first quarter of last year [8][104] - Nelson Labs experienced a revenue decline of 2.3% to $52 million, with segment income down over 17% to $14 million [109][86] - Nordion's revenue declined approximately 75% to $9 million, driven by the timing of cobalt-60 harvest supply schedules [25][85] Market Data and Key Metrics Changes - The potential impact of the complete loss of cobalt-60 supply from Russia on total Sotera Health 2023 revenues is now estimated at 0% to 2.5% [12][105] - The company expects to see increased volumes and margin expansion throughout the year for both Sterigenics and Nelson Labs [12][106] Company Strategy and Development Direction - The company is investing in additional capacity with six active expansion projects at Sterigenics and enhancements to EO facilities in North America [4][28] - The mission of safeguarding global health remains central to the company's operations, focusing on providing critical scientific expertise and regulatory consulting [6][5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the 2023 revenue forecast despite irregular timing of Nordion's revenue, with approximately 75% expected in the second half of the year [21][22] - The company anticipates total revenues for 2023 to be in the range of $1.055 billion to $1.090 billion, representing an annual growth rate of 5% to 9% [11][106] Other Important Information - The company generated approximately $34 million of operating cash flow during the quarter, with $648 million in cash and cash equivalents as of March 31, 2023 [26][27] - Capital expenditures are expected to be in the range of $185 million to $215 million, focusing on growth and capacity expansions [28][91] Q&A Session Summary Question: Any twists and turns in the segments relative to your prior plan? - Management indicated that there were no significant changes in the outlook for the segments compared to previous expectations [15][19] Question: Can you provide clarity on Nelson Labs' volume recovery? - Management noted that the first quarter is typically the lowest for Nelson Labs, but they expect volumes to pick up as the year progresses [14][43] Question: What is the expected impact of the EPA proposed regulations? - Management acknowledged the aggressive timeline for compliance but expressed confidence in their ability to meet the new standards due to prior investments [68][70] Question: How is the company positioned regarding the cobalt-60 supply? - Management confirmed that there was no disruption in supply during the first quarter and that they are well-positioned for the year [12][105] Question: What are the expectations for pricing and inflation? - Management expects pricing to settle in the range of 3.5% to 5% per year, with Sterigenics in the middle of that range [115][95]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39729 SOTERA HEALTH COMPANY (Exact name of registrant as specified in its charter) | Delaware | | 47-3531161 | ...